The KRAS-Variant and Cetuximab in HPV-Positive Oropharyngeal Cancer: Results from the NRG/RTOG 1016 Trial.

Cancer Res Commun · 2026 · PMC13036839 · PMID 41790036

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a nonsignificant trendno p-value reported

However, there was a nonsignificant trend for a lower rate of LRF with cetuximab for the KRAS- variant subgroup of patients, in contrast to what is seen in nonvariant patients who exhibit a significantly higher risk of LRF.

also in 5,406 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.